Retatrutide

Retatrutide
A$180.00

Product Name

Retatrutide

Concentration

10 mg

Presentation

Lyophilised powder in a 3 mL vial

Suggested Diluent

Bacteriostatic water (for laboratory research use only)

Product Summary

Retatrutide is an investigational peptide currently being studied in metabolic and endocrinology research. It is classified as a triple incretin receptor agonist (GGG tri-agonist), meaning it demonstrates activity at the GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR) in research settings.

Preclinical and clinical research publications describe retatrutide as a compound designed to target multiple metabolic pathways involved in energy balance, appetite regulation, and fat metabolism. Unlike single- or dual-incretin agonists, retatrutide has been engineered to combine appetite suppression pathways with mechanisms associated with increased energy expenditure.

In published clinical research, retatrutide has demonstrated significant reductions in body weight and fat mass in study participants, making it a compound of interest for ongoing metabolic research. These findings relate to controlled research environments only and do not constitute approved therapeutic use.

Mechanism of Action (Research Context)

In vivo and clinical research indicates that retatrutide functions as a full agonist at:

  • Glucose-dependent insulinotropic polypeptide receptor (GIPR)

  • Glucagon-like peptide-1 receptor (GLP-1R)

  • Glucagon receptor (GCGR)

Activation of GLP-1R and GIPR is associated in research with:

  • Delayed gastric emptying

  • Central appetite and satiety signalling

  • Reduced caloric intake

Activation of the glucagon receptor (GCGR) has been associated in research models with:

  • Increased energy expenditure

  • Enhanced fat oxidation

Published data suggest that the combined receptor activity results in a greater and more sustained reduction in food intake compared with single-pathway incretin peptides, with weight reduction driven predominantly by loss of fat mass rather than lean tissue.

Research Status

  • Retatrutide is an unapproved investigational compound

  • It is currently being evaluated in clinical trials

  • It is not included on the Australian Register of Therapeutic Goods (ARTG)

  • Long-term safety and efficacy have not been established

Storage and Handling (Research Use Only)

  • Supplied as a lyophilised powder

  • Store refrigerated at 2–8°C for long-term storage

  • Short periods at ambient temperature during transport are acceptable

  • Reconstitution should only be performed using appropriate laboratory technique

Important Regulatory & Safety Notice (Australia)

This product is supplied strictly for laboratory research purposes only.

  • Not a therapeutic good under the Therapeutic Goods Act 1989 (Cth)

  • Not approved by the Therapeutic Goods Administration (TGA)

  • Not intended for human or animal consumption

  • Not intended to diagnose, treat, cure, or prevent any disease

  • No dosage, administration, or medical guidance is provided or implied

Purchase and use of this product must comply with all applicable Australian laws and regulations. The buyer assumes full responsibility for lawful handling and use.

Summary

Retatrutide represents a next-generation triple incretin agonist of significant interest in metabolic research. Its combined receptor activity distinguishes it from earlier incretin compounds and has made it a focus of ongoing scientific investigation. However, it remains an experimental, non-therapeutic substance, and all references to effects relate solely to controlled research settings.